Download
-+ 0.00%
-+ 0.00%
-+ 0.00%
Haemonetics Q2 FY27 net income rises 20% to $46.3 million; Q2 FY27 revenue climbs 9% to $357.8 million
Share
Listen to the news
Haemonetics Q2 FY27 net income rises 20% to $46.3 million; Q2 FY27 revenue climbs 9% to $357.8 million
  • Haemonetics’ second-quarter FY27 earnings per diluted share rose 23% year over year to $1.
  • Revenue climbed 9% year over year to $357.8 million.
  • CEO Chris Simon highlighted expansion of the CSL relationship and innovation milestones in Apheresis and MedSurg.
  • FY27 reported revenue growth guidance increased to 8%–11%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending